Bayer HealthCare, the clinical jobs provider, has highlighted new trial data to support the effectiveness of its drug Xarelto in preventing strokes among atrial fibrillation patients.
Reported in the New England Journal of Medicine, the Rocket AF phase III clinical trial saw the medicine compared to warfarin where sufferers had been recommended oral anticoagulation.
As part of the study, data revealed that Xarelto offered a higher quality of efficacy by a number of metrics.
In addition, scientists found that serious adverse effects in terms of overall bleeding rates were shown to be lower with use of the Bayer HealthCare medicine.
The drug, which is a rivaroxaban-based therapy, was developed as part of a joint venture between the pharmaceutical company and Johnson and Johnson for a range of applications.
News of the treatment's success emerges after similarly promising results were achieved from a Japanese study of J-Rocket AF during clinical trials last month.